

# Christian E Badr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5847524/publications.pdf>

Version: 2024-02-01

37  
papers

1,716  
citations

430754

18  
h-index

477173

29  
g-index

41  
all docs

41  
docs citations

41  
times ranked

6021  
citing authors

#	ARTICLE	IF	CITATIONS
1	Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. <i>Nature Communications</i> , 2015, 6, 7029.	5.8	449
2	A secreted luciferase for ex vivo monitoring of in vivo processes. <i>Nature Methods</i> , 2008, 5, 171-173.	9.0	263
3	Bioluminescence imaging: progress and applications. <i>Trends in Biotechnology</i> , 2011, 29, 624-633.	4.9	240
4	A Highly Sensitive Assay for Monitoring the Secretory Pathway and ER Stress. <i>PLoS ONE</i> , 2007, 2, e571.	1.1	123
5	Triple Bioluminescence Imaging for In Vivo Monitoring of Cellular Processes. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e99.	2.3	77
6	Stearoyl CoA Desaturase Is Essential for Regulation of Endoplasmic Reticulum Homeostasis and Tumor Growth in Glioblastoma Cancer Stem Cells. <i>Stem Cell Reports</i> , 2019, 12, 712-727.	2.3	62
7	Real-Time Monitoring of Nuclear Factor $\kappa$ B Activity in Cultured Cells and in Animal Models. <i>Molecular Imaging</i> , 2009, 8, 7290.2009.00026.	0.7	56
8	Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. <i>Neuro-Oncology</i> , 2011, 13, 1213-1224.	0.6	52
9	Real-time monitoring of nuclear factor $\kappa$ B activity in cultured cells and in animal models. <i>Molecular Imaging</i> , 2009, 8, 278-90.	0.7	49
10	Bioluminescence Imaging: Basics and Practical Limitations. <i>Methods in Molecular Biology</i> , 2014, 1098, 1-18.	0.4	48
11	Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models. <i>Neuro-Oncology</i> , 2017, 19, now253.	0.6	35
12	Metabolic heterogeneity and adaptability in brain tumors. <i>Cellular and Molecular Life Sciences</i> , 2020, 77, 5101-5119.	2.4	34
13	Functional Drug Screening Assay Reveals Potential Glioma Therapeutics. <i>Assay and Drug Development Technologies</i> , 2011, 9, 281-289.	0.6	31
14	Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery. <i>Journal of Neuro-Oncology</i> , 2018, 139, 293-305.	1.4	24
15	Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16017.	2.0	21
16	Targeting Cancer Cells With the Natural Compound Obtusaquinone. <i>Journal of the National Cancer Institute</i> , 2013, 105, 643-653.	3.0	19
17	Systemic Anticancer Neural Stem Cells in Combination with a Cardiac Glycoside for Glioblastoma Therapy. <i>Stem Cells</i> , 2014, 32, 2021-2032.	1.4	18
18	Intracranial AAV9-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. <i>Molecular Oncology</i> , 2016, 10, 625-634.	2.1	18

#	ARTICLE	IF	CITATIONS
19	Sustained NF- $\kappa$ B-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a vulnerability to EZH2 inhibition. <i>Cell Death Discovery</i> , 2019, 5, 72.	2.0	18
20	Obtusaquinone: A Cysteine-Modifying Compound That Targets Keap1 for Degradation. <i>ACS Chemical Biology</i> , 2020, 15, 1445-1454.	1.6	18
21	Suicidal gene therapy in an NF- $\kappa$ B-controlled tumor environment as monitored by a secreted blood reporter. <i>Gene Therapy</i> , 2011, 18, 445-451.	2.3	15
22	Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A. <i>Biochemical Pharmacology</i> , 2021, 183, 114317.	2.0	13
23	A multiplexed bioluminescent reporter for sensitive and non-invasive tracking of DNA double strand break repair dynamics in vitro and in vivo. <i>Nucleic Acids Research</i> , 2020, 48, e100-e100.	6.5	10
24	A TNF-NF- $\kappa$ B-STAT3 loop triggers resistance of glioma-stem-like cells to Smac mimetics while sensitizing to EZH2 inhibitors. <i>Cell Death and Disease</i> , 2019, 10, 268.	2.7	8
25	Multiplexed bioluminescence-mediated tracking of DNA double-strand break repairs in vitro and in vivo. <i>Nature Protocols</i> , 2021, 16, 3933-3953.	5.5	6
26	An allosteric inhibitor of SHP2 effectively targets PDGFR $\alpha$ -driven glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1348-1349.	0.6	4
27	Intranasal delivery of experimental compounds in orthotopic brain tumor mouse models. <i>STAR Protocols</i> , 2021, 2, 100290.	0.5	2
28	Cell-Based Bioluminescence Screening Assays. <i>Methods in Molecular Biology</i> , 2014, 1098, 185-195.	0.4	1
29	Gussia luciferase blood level as an index of cell growth and proliferation. <i>Protocol Exchange</i> , 0, , .	0.3	1
30	Orthotopic brain tumor models derived from glioblastoma stem-like cells. <i>Methods in Cell Biology</i> , 2022, , .	0.5	1
31	956. Imaging of Radiation-Inducible Promoters Using a Naturally Secreted Luciferase from the Marine Copepod <i>Gussia princeps</i> . <i>Molecular Therapy</i> , 2006, 13, S369.	3.7	0
32	STEM-18.CULTURE CONDITION-INDUCED MESENCHYMAL TRANSITION IN PATIENT-DERIVED GLIOBLASTOMA STEM CELLS. <i>Neuro-Oncology</i> , 2015, 17, v211.5-v212.	0.6	0
33	STEM-16. TARGETING THE SCF UBIQUITIN LIGASE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi229-vi229.	0.6	0
34	DDRE-11. TARGETING FATTY ACID BIOSYNTHESIS IN GLIOBLASTOMA. <i>Neuro-Oncology Advances</i> , 2021, 3, i8-i8.	0.4	0
35	DDRE-05. STEAROYL COA DESATURASE IS ESSENTIAL FOR REGULATION OF ENDOPLASMIC RETICULUM HOMEOSTASIS AND TUMOR GROWTH IN GLIOBLASTOMA CANCER STEM CELLS. <i>Neuro-Oncology Advances</i> , 2021, 3, i7-i7.	0.4	0
36	Abstract A254: Systemic injection of human neural stem cells expressing anti-cancer agent targets invasive gliomas and induces tumor regression in combination with a cardiac glycoside.. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
37	EXTH-23. PRECLINICAL EFFICACY OF A TARGETED, BRAIN PENETRANT INHIBITOR OF FATTY ACID DESATURATION IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi168-vi168.	0.6	0